{"id":"ipilimumab-injection","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Immune-related colitis"},{"rate":"2-5","effect":"Immune-related hepatitis"},{"rate":"1-3","effect":"Immune-related pneumonitis"},{"rate":"5-10","effect":"Immune-related endocrinopathy (thyroiditis, hypophysitis)"},{"rate":"25-30","effect":"Rash"},{"rate":"20-30","effect":"Fatigue"},{"rate":"20-30","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ipilimumab is a monoclonal antibody that binds to cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), a negative regulator of T-cell activation. By blocking CTLA-4, the drug removes a 'brake' on the immune system, allowing T cells to become more activated and proliferate. This enhanced immune activation enables the body's own immune cells to recognize and attack cancer cells more effectively.","oneSentence":"Ipilimumab blocks CTLA-4 on T cells, removing an inhibitory signal and enhancing anti-tumor immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:02.170Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic melanoma"},{"name":"Advanced or metastatic colorectal cancer (in combination with nivolumab)"},{"name":"Metastatic non-small cell lung cancer (in combination with nivolumab)"}]},"trialDetails":[{"nctId":"NCT05665348","phase":"PHASE2, PHASE3","title":"Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2023-03-09","conditions":"HCC - Hepatocellular Carcinoma, Metastatic Cancer, Metastatic Tumor","enrollment":229},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT07430202","phase":"PHASE1","title":"A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)","status":"NOT_YET_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-05","conditions":"Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))","enrollment":27},{"nctId":"NCT06353646","phase":"NA","title":"XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer","status":"RECRUITING","sponsor":"Wu Wenming","startDate":"2024-03-12","conditions":"Pancreatic Cancer","enrollment":28},{"nctId":"NCT07230613","phase":"PHASE2","title":"Neo-adjuvant Immunotherapy in Patients With Localized Melanoma","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2026-01-12","conditions":"Cutaneous Melanoma, Stage III, Mucosal Melanoma","enrollment":50},{"nctId":"NCT00586391","phase":"PHASE1","title":"CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2009-02","conditions":"B Cell Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia","enrollment":14},{"nctId":"NCT05533697","phase":"PHASE1, PHASE2","title":"Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2022-09-01","conditions":"Advanced Solid Tumors","enrollment":361},{"nctId":"NCT07349225","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"The Second Affiliated Hospital of Dalian Medical University","startDate":"2026-01-31","conditions":"ES-SCLC","enrollment":46},{"nctId":"NCT05428007","phase":"PHASE2","title":"Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2023-02-02","conditions":"Melanoma, Unresectable Melanoma","enrollment":105},{"nctId":"NCT03929029","phase":"PHASE1","title":"Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-11-11","conditions":"Cutaneous Melanoma","enrollment":11},{"nctId":"NCT04079166","phase":"PHASE2","title":"SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Scancell Ltd","startDate":"2019-08-19","conditions":"Malignant Melanoma, Melanoma (Skin), Melanoma Stage III","enrollment":173},{"nctId":"NCT06889493","phase":"PHASE1","title":"SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)","status":"RECRUITING","sponsor":"Peter Hosein, MD","startDate":"2025-05-19","conditions":"Neuroendocrine Carcinoma, Neuroendocrine Tumors","enrollment":36},{"nctId":"NCT05631899","phase":"PHASE1","title":"CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2023-04-03","conditions":"Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V","enrollment":9},{"nctId":"NCT03233152","phase":"PHASE1, PHASE2","title":"A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2016-11-17","conditions":"Glioblastoma","enrollment":110},{"nctId":"NCT02668770","phase":"PHASE1","title":"Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-05-11","conditions":"Advanced Cancers, Melanoma","enrollment":28},{"nctId":"NCT03949153","phase":"PHASE1, PHASE2","title":"Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2019-08-16","conditions":"Melanoma (Skin)","enrollment":19},{"nctId":"NCT05721846","phase":"PHASE1","title":"Nivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Inna Chen, MD","startDate":"2023-05-03","conditions":"Pancreatic Cancer","enrollment":20},{"nctId":"NCT02890329","phase":"PHASE1","title":"Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-09-05","conditions":"Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Myelodysplasia-Related","enrollment":54},{"nctId":"NCT02020070","phase":"PHASE2","title":"Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-12-18","conditions":"Metastatic Castration Sensitive Prostate Cancer","enrollment":16},{"nctId":"NCT03235245","phase":"PHASE2","title":"Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2018-10-30","conditions":"Unresectable Stage III Melanoma, Stage IV Melanoma","enrollment":271},{"nctId":"NCT03350126","phase":"PHASE2","title":"iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2017-12-04","conditions":"Metastatic Cancer Colorectal","enrollment":57},{"nctId":"NCT05444530","phase":"PHASE1","title":"A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-21","conditions":"Myeloproliferative Neoplasms","enrollment":14},{"nctId":"NCT06903312","phase":"PHASE4","title":"Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2025-06-15","conditions":"Renal Cell Cancer, Kidney Neoplasm, Immunotherapy","enrollment":409},{"nctId":"NCT03918252","phase":"PHASE2","title":"Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-10-02","conditions":"Mesothelioma","enrollment":30},{"nctId":"NCT04006262","phase":"PHASE2","title":"Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2019-10-23","conditions":"Localized Oesogastric Adenocarcimona, MSI and or dMMR","enrollment":32},{"nctId":"NCT05141721","phase":"PHASE2, PHASE3","title":"A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seattle Project Corporation","startDate":"2022-02-12","conditions":"Colorectal Neoplasms","enrollment":700},{"nctId":"NCT03618641","phase":"PHASE2","title":"CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease","status":"COMPLETED","sponsor":"Diwakar Davar","startDate":"2018-08-08","conditions":"Melanoma, Lymph Node Cancer","enrollment":34},{"nctId":"NCT03477864","phase":"PHASE1","title":"Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2018-12-24","conditions":"Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer","enrollment":""},{"nctId":"NCT05144529","phase":"PHASE2","title":"A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Scott Antonia","startDate":"2022-03-22","conditions":"Lung Cancer Metastatic","enrollment":38},{"nctId":"NCT05012254","phase":"PHASE2","title":"Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación GECP","startDate":"2021-11-18","conditions":"Non Small Cell Lung Cancer, Brain Metastases, Adult, Lung Cancer","enrollment":71},{"nctId":"NCT02812524","phase":"PHASE1","title":"Ipilimumab for Head and Neck Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Providence Health & Services","startDate":"2016-11-18","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":18},{"nctId":"NCT03158129","phase":"PHASE2","title":"Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-06-16","conditions":"Stage I Lung Non-Small Cell Cancer AJCC v7, Stage IA Lung Non-Small Cell Carcinoma AJCC v7, Stage IB Lung Non-Small Cell Carcinoma AJCC v7","enrollment":101},{"nctId":"NCT03058289","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6","status":"COMPLETED","sponsor":"Intensity Therapeutics, Inc.","startDate":"2017-02-09","conditions":"Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma","enrollment":111},{"nctId":"NCT06841185","phase":"PHASE3","title":"A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2025-04-30","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":656},{"nctId":"NCT05457959","phase":"PHASE1","title":"Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant","status":"WITHDRAWN","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-12-01","conditions":"Diffuse Hemispheric Glioma, H3 G34-Mutant","enrollment":""},{"nctId":"NCT06097975","phase":"PHASE1","title":"A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma","status":"RECRUITING","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2024-03-15","conditions":"Recurrent Glioblastoma","enrollment":18},{"nctId":"NCT03707808","phase":"PHASE1, PHASE2","title":"Intratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab","status":"RECRUITING","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2018-01-29","conditions":"Solid Tumor, Metastases to Soft Tissue","enrollment":18},{"nctId":"NCT06364631","phase":"PHASE3","title":"CARE1 Pragmatic Clinical Trial","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2024-04-12","conditions":"Metastatic Kidney Cancer, Metastatic Kidney Carcinoma","enrollment":1250},{"nctId":"NCT05456165","phase":"PHASE2","title":"Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer","status":"WITHDRAWN","sponsor":"Gritstone bio, Inc.","startDate":"2022-05-19","conditions":"Colonic Neoplasms, Colorectal Neoplasms","enrollment":""},{"nctId":"NCT03153085","phase":"PHASE2","title":"A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma","status":"COMPLETED","sponsor":"Takara Bio Inc.","startDate":"2017-05-25","conditions":"Melanoma Stage III, Melanoma Stage IV","enrollment":28},{"nctId":"NCT03296137","phase":"PHASE1, PHASE2","title":"Adoptive Cell Therapy Across Cancer Diagnoses","status":"COMPLETED","sponsor":"Inge Marie Svane","startDate":"2017-10-13","conditions":"Cancer","enrollment":25},{"nctId":"NCT04401995","phase":"PHASE2","title":"Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab","status":"COMPLETED","sponsor":"Diwakar Davar","startDate":"2020-09-02","conditions":"Melanoma","enrollment":9},{"nctId":"NCT04270864","phase":"PHASE1","title":"Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers","status":"TERMINATED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2020-04-10","conditions":"Advanced Cancer","enrollment":25},{"nctId":"NCT05655715","phase":"PHASE2","title":"Checkpoint Inhibitors and SBRT for MCRPC","status":"COMPLETED","sponsor":"Herlev and Gentofte Hospital","startDate":"2019-11-25","conditions":"Prostate Cancer Metastatic, Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":90},{"nctId":"NCT03879512","phase":"PHASE1, PHASE2","title":"Autologous Dendritic Cells, Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGG","status":"COMPLETED","sponsor":"Wuerzburg University Hospital","startDate":"2018-02-07","conditions":"Childhood Glioblastoma","enrollment":24},{"nctId":"NCT04770207","phase":"PHASE2","title":"Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2020-11-01","conditions":"Hepatocellular Carcinoma, Solid Tumor, Adult","enrollment":100},{"nctId":"NCT04823403","phase":"PHASE1","title":"Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2020-11-13","conditions":"Hepatocellular Carcinoma","enrollment":27},{"nctId":"NCT04739618","phase":"PHASE2","title":"Metastatic Solid Cancer Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunSYS, LLC","startDate":"2021-03-04","conditions":"Metastatic Cancer","enrollment":32},{"nctId":"NCT06492408","phase":"PHASE2","title":"Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2024-07-01","conditions":"Hepatic Cancer, Surgery","enrollment":90},{"nctId":"NCT06492421","phase":"PHASE2","title":"Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2024-07-01","conditions":"Lung Cancer, Surgery, Non-small Cell Lung Cancer","enrollment":90},{"nctId":"NCT06483347","phase":"PHASE2","title":"Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2024-04-04","conditions":"Lung Cancer, Inoperable Disease","enrollment":90},{"nctId":"NCT06482801","phase":"PHASE2","title":"Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2024-06-10","conditions":"Liver Cancer, Antibody","enrollment":90},{"nctId":"NCT03755739","phase":"PHASE2, PHASE3","title":"Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2018-11-01","conditions":"Hepatocarcinoma, Lung Cancer, Melanoma","enrollment":200},{"nctId":"NCT05187338","phase":"PHASE1, PHASE2","title":"Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2021-11-01","conditions":"Lung Cancer, Liver Cancer, Colorectal Cancer","enrollment":100},{"nctId":"NCT05116917","phase":"PHASE2","title":"Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.","status":"TERMINATED","sponsor":"Herlev Hospital","startDate":"2021-11-05","conditions":"Pancreatic Cancer","enrollment":19},{"nctId":"NCT04480502","phase":"PHASE2","title":"ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tracon Pharmaceuticals Inc.","startDate":"2020-12-09","conditions":"Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma","enrollment":207},{"nctId":"NCT01740297","phase":"PHASE1, PHASE2","title":"Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-02-07","conditions":"Melanoma","enrollment":217},{"nctId":"NCT04713371","phase":"PHASE2","title":"A Phase 2 Trial for Patients With Metastatic Solid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rampart Health, L.L.C.","startDate":"2021-05-19","conditions":"Metastatic Cancer","enrollment":32},{"nctId":"NCT03711188","phase":"PHASE2","title":"A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma","status":"COMPLETED","sponsor":"Immodulon Therapeutics Ltd","startDate":"2018-10-04","conditions":"Melanoma","enrollment":16},{"nctId":"NCT04291755","phase":"","title":"Development and Analysis of a Stool Bank for Cancer Patients","status":"RECRUITING","sponsor":"Persephone Biosciences","startDate":"2019-06-28","conditions":"Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal","enrollment":100},{"nctId":"NCT04899921","phase":"PHASE2","title":"Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-06-30","conditions":"Melanoma, Metastatic Melanoma","enrollment":1},{"nctId":"NCT04840615","phase":"PHASE1","title":"Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-11","conditions":"Mesothelioma","enrollment":2},{"nctId":"NCT01769222","phase":"PHASE1","title":"Ipilimumab and Local Radiation for Selected Solid Tumors","status":"TERMINATED","sponsor":"Stanford University","startDate":"2013-02","conditions":"Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma","enrollment":3},{"nctId":"NCT05492123","phase":"PHASE2","title":"Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer","status":"RECRUITING","sponsor":"Hospital Israelita Albert Einstein","startDate":"2022-08-30","conditions":"Uterine Cervical Neoplasms","enrollment":112},{"nctId":"NCT04118166","phase":"PHASE2","title":"Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Kristen Ganjoo","startDate":"2019-10-01","conditions":"Soft Tissue Sarcoma","enrollment":30},{"nctId":"NCT06159101","phase":"PHASE1","title":"A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2023-11-28","conditions":"Healthy Male Volunteers","enrollment":304},{"nctId":"NCT05284214","phase":"PHASE2","title":"Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors","status":"WITHDRAWN","sponsor":"Partner Therapeutics, Inc.","startDate":"2024-01","conditions":"Solid Tumor, Solid Tumor, Adult","enrollment":""},{"nctId":"NCT05631886","phase":"PHASE1","title":"Combination of CAR-DC Vaccine and ICIs in Malignant Tumors","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2023-07-04","conditions":"Solid Tumor, Adult, Lymphoma, EphA2 Overexpression","enrollment":10},{"nctId":"NCT01176474","phase":"PHASE1","title":"Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2010-08-13","conditions":"Melanoma (Skin)","enrollment":73},{"nctId":"NCT03563729","phase":"PHASE2","title":"Melanoma Metastasized to the Brain and Steroids","status":"RECRUITING","sponsor":"Inge Marie Svane","startDate":"2018-06-06","conditions":"Malignant Melanoma","enrollment":80},{"nctId":"NCT02154490","phase":"","title":"Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2014-07-08","conditions":"Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7","enrollment":1864},{"nctId":"NCT03507699","phase":"PHASE1","title":"Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Sheba Medical Center","startDate":"2018-12-15","conditions":"Colorectal Neoplasms Malignant, Liver Metastases","enrollment":19},{"nctId":"NCT03287674","phase":"PHASE1, PHASE2","title":"TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer","status":"COMPLETED","sponsor":"Inge Marie Svane","startDate":"2017-10-09","conditions":"Metastatic Ovarian Cancer","enrollment":7},{"nctId":"NCT02857569","phase":"PHASE1, PHASE2","title":"A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-12-05","conditions":"Stage III/IV Melanoma","enrollment":90},{"nctId":"NCT02307149","phase":"PHASE1","title":"Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)","status":"COMPLETED","sponsor":"Viralytics","startDate":"2015-05-05","conditions":"Melanoma","enrollment":50},{"nctId":"NCT03445533","phase":"PHASE3","title":"A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma","status":"TERMINATED","sponsor":"Idera Pharmaceuticals, Inc.","startDate":"2018-05-30","conditions":"Metastatic Melanoma","enrollment":481},{"nctId":"NCT01838200","phase":"PHASE1","title":"Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma","status":"TERMINATED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2014-03","conditions":"Metastatic Melanoma","enrollment":5},{"nctId":"NCT01810016","phase":"PHASE1","title":"NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma","status":"TERMINATED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2014-01-24","conditions":"Unresectable or Metastatic Melanoma","enrollment":8},{"nctId":"NCT04571632","phase":"PHASE2","title":"Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors","status":"UNKNOWN","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2020-09-22","conditions":"Non Small Cell Lung Cancer, Solid Tumor","enrollment":36},{"nctId":"NCT03532217","phase":"PHASE1","title":"Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2018-09-14","conditions":"Metastatic Hormone-Sensitive Prostate Cancer","enrollment":19},{"nctId":"NCT02644967","phase":"PHASE2","title":"A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"Idera Pharmaceuticals, Inc.","startDate":"2015-12","conditions":"Metastatic Melanoma","enrollment":53},{"nctId":"NCT02977156","phase":"PHASE1","title":"Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors.","status":"COMPLETED","sponsor":"Centre Leon Berard","startDate":"2017-01-03","conditions":"Metastatic Tumor, Advanced Tumor","enrollment":22},{"nctId":"NCT04090775","phase":"PHASE2","title":"A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma","status":"COMPLETED","sponsor":"Rampart Health, L.L.C.","startDate":"2019-06-28","conditions":"Metastatic Prostatic Adenocarcinoma","enrollment":12},{"nctId":"NCT03865082","phase":"PHASE2","title":"Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Idera Pharmaceuticals, Inc.","startDate":"2019-10-29","conditions":"Solid Tumor","enrollment":30},{"nctId":"NCT03177239","phase":"PHASE2","title":"Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)","status":"UNKNOWN","sponsor":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","startDate":"2017-10-19","conditions":"Renal Cell Carcinoma, Papillary Renal Cell Carcinoma Type 1, Papillary Renal Cell Carcinoma Type 2","enrollment":85},{"nctId":"NCT02675439","phase":"PHASE1","title":"Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas","status":"TERMINATED","sponsor":"Chinook Therapeutics, Inc. (formerly Aduro)","startDate":"2016-04-28","conditions":"Advanced/Metastatic Solid Tumors or Lymphomas","enrollment":47},{"nctId":"NCT03422094","phase":"PHASE1","title":"Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2018-10-31","conditions":"Glioblastoma","enrollment":3},{"nctId":"NCT03056599","phase":"PHASE1","title":"Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Presage Biosciences","startDate":"2016-12-15","conditions":"Soft Tissue Sarcoma Adult","enrollment":23},{"nctId":"NCT01840579","phase":"PHASE1","title":"Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-04-26","conditions":"Solid Tumor, Non-small Cell Lung Cancer, Small Cell Lung Cancer","enrollment":57},{"nctId":"NCT02913417","phase":"PHASE1, PHASE2","title":"Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases","status":"UNKNOWN","sponsor":"David Minor, MD","startDate":"2016-10-10","conditions":"Uveal Melanoma, Hepatic Metastases","enrollment":26},{"nctId":"NCT03313323","phase":"PHASE2","title":"Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma","status":"UNKNOWN","sponsor":"Amsterdam UMC, location VUmc","startDate":"2017-02-16","conditions":"Melanoma","enrollment":29},{"nctId":"NCT04021420","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With Melanoma","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-10-24","conditions":"Melanoma, Metastatic Melanoma","enrollment":21},{"nctId":"NCT03695835","phase":"","title":"A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen.","status":"COMPLETED","sponsor":"Gary Onik MD","startDate":"2018-04-11","conditions":"Adenocarcinoma","enrollment":27},{"nctId":"NCT01896869","phase":"PHASE2","title":"FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2013-11","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":83},{"nctId":"NCT02174172","phase":"PHASE1","title":"A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-08-18","conditions":"Solid Cancers","enrollment":158},{"nctId":"NCT04274816","phase":"PHASE1","title":"Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma","status":"COMPLETED","sponsor":"A.J.M. van den Eertwegh","startDate":"2012-07-10","conditions":"Cutaneous Melanoma","enrollment":13},{"nctId":"NCT02254772","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of Intratumoral Injection of SD-101","status":"COMPLETED","sponsor":"Robert Lowsky","startDate":"2014-09","conditions":"Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma","enrollment":9},{"nctId":"NCT02279862","phase":"PHASE2","title":"Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-12-02","conditions":"Prostate Cancer","enrollment":82},{"nctId":"NCT02279732","phase":"PHASE3","title":"Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-10-13","conditions":"Lung Cancer (NSCLC)","enrollment":342},{"nctId":"NCT03784040","phase":"PHASE1","title":"Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study.","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2019-02-21","conditions":"Gastric Cancer","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Atezolizumab","Bevacizumab","Yervoy","BMS-734016","MDX010"],"phase":"phase_3","status":"active","brandName":"Ipilimumab Injection","genericName":"Ipilimumab Injection","companyName":"Federation Francophone de Cancerologie Digestive","companyId":"federation-francophone-de-cancerologie-digestive","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ipilimumab blocks CTLA-4 on T cells, removing an inhibitory signal and enhancing anti-tumor immune responses. Used for Metastatic melanoma, Advanced or metastatic colorectal cancer (in combination with nivolumab), Metastatic non-small cell lung cancer (in combination with nivolumab).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}